Peptide-Based Imaging Agent for Peripheral Nerve Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging agents for nerve tissue lack specificity for the peripheral nervous system, often staining adipose tissue and the central nervous system, leading to unwanted systemic side effects and reduced visibility of nerve tissue during surgical procedures.
Innovation Solution
Development of a compound comprising a peptide with at least 80% sequence identity to the extracellular domain of myelin protein-zero (P0), combined with a detectable imaging label, to specifically target and image nerve tissue in the peripheral nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If non-targeted fluorescent dyes or peptides are used for nerve imaging, then nerve tissue can be visualized, but the agents also stain adipose tissue and central nervous system, reducing specificity and increasing systemic side effects
Solution Approach 1:
The patent applies local quality by designing a peptide probe with specific biochemical properties that enable selective binding to peripheral nerve tissue components (such as myelin proteins or nerve-specific receptors) while excluding binding to adipose tissue or central nervous system structures. This is achieved through targeted molecular recognition elements in the peptide sequence that match specific antigens or binding sites present only in peripheral nerves, thereby conferring local specificity to the imaging agent.
Solution Approach 2:
The patent employs parameter changes by modifying key characteristics of the imaging agent, specifically the peptide sequence composition, molecular size, charge distribution, or hydrophobicity, to optimize affinity for peripheral nerve targets while minimizing non-specific binding. By adjusting these biochemical parameters, the probe achieves enhanced selectivity for peripheral nerve tissue over other tissue types, resolving the contradiction between visibility and specificity.
2Reliability
If imaging agents with high nerve tissue affinity are developed, then nerve visibility improves, but the agents may lose systemic safety due to non-specific binding in other tissues
Solution Approach 1:
The patent applies segmentation by dividing the imaging agent into distinct functional modules: a targeting peptide segment with high specificity for peripheral nerve structures, and a fluorescent reporter segment for detection. This modular design allows independent optimization of binding affinity and imaging properties, enabling high nerve visibility while maintaining systemic safety through precise targeting control in the peptide segment.
Solution Approach 2:
The patent uses an intermediary mechanism where the peptide probe acts as a selective mediator between the imaging system and peripheral nerve tissue. The peptide's specific biochemical interactions with nerve components (such as myelin basic protein or nerve growth factor receptors) enable targeted accumulation at the nerve site without triggering non-specific binding in other tissues, thus mediating high visibility while eliminating harmful off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-based imaging agent provides high specificity for peripheral nerve tissue, reducing accidental nerve injury during surgery and enabling precise visualization of nerve structures, thereby improving surgical outcomes and diagnostic accuracy.
Implementation Method 1
a peptide that specifically binds to a surface marker of the peripheral nervous system
Data Source
AI summary
The present invention relates to compounds comprising a peptide and a detectable imaging label, their use as imaging and diagnostic agents and their use in imaging of a neuron, an axon, a nerve or nerve tissue, preferably of the peripheral nervous system, in image-guided surgery and for determining whether an individual is suffering from a myelin related disorder or from nerve tissue damage.